Conference

Kidney Week 2026: Keto Therapy Data in Advanced ADPKD

At ASN Kidney Week 2026, a patient moved from CKD stage 4 to stage 3b on ketogenic therapy, and Cologne researchers showed how a keto diet reshapes kidney signaling.

Ketogenic metabolic therapy featured in several ADPKD abstracts at ASN Kidney Week 2026 in Denver (October 22–25), including the first report of kidney function improving in advanced disease.

Melina Messing, Emily Muensterman and Thomas Weimbs (UC Santa Barbara and Santa Barbara Nutrients) described a 66-year-old woman with advanced ADPKD who had been on tolvaptan for about 18 years and whose eGFR had fallen from 32 to 20 mL/min/1.73m² between 2023 and June 2025. She joined the Ren-Nu ketogenic program, including daily KetoCitra, in August 2025 while continuing tolvaptan. From June to December 2025, her serum creatinine fell from 2.62 to 1.90 mg/dL and cystatin C from 2.26 to 1.72 mg/L. Her combined eGFR rose from 21.8 to 32.2 mL/min/1.73m², a move from CKD stage 4 to stage 3b in six months. Blood urea nitrogen, phosphorus and uric acid also fell, and she reported marked improvements in energy and quality of life. The authors conclude that meaningful improvement may still be achievable in later-stage ADPKD.

From Cologne, Marvin Droste, Roman-Ulrich Mueller and colleagues analysed urinary extracellular vesicles, tiny packages of kidney proteins shed into urine, from 40 participants in the KETO-ADPKD trial. The ketogenic diet group showed a strong metabolic signature of adaptation to low glucose. Proteins linked to the kinds of cell death that drive fibrosis were reduced, as were proteins in mTOR signaling, a key growth pathway in cysts. Substantially more proteins changed with the ketogenic diet than with water fasting. This is some of the first molecular evidence from human kidneys of what animal studies have long suggested about how ketosis acts in PKD.

The Weimbs group also presented its long-term case series of patients on ketogenic therapy with KetoCitra, published earlier this year in Frontiers in Nutrition, which showed stabilization or reduction of kidney volume relative to prior growth trends.

Source

ASN Kidney Week 2026
ketogenic-diet KetoCitra ASN-2026 kidney-week advanced-ckd

Disclaimer: This information is for educational purposes only and is not medical advice. News articles are based on publicly available data from ClinicalTrials.gov, company press releases, and published research. Consult your nephrologist before making treatment decisions.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.